<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05038696</url>
  </required_header>
  <id_info>
    <org_study_id>2020/00865</org_study_id>
    <nct_id>NCT05038696</nct_id>
  </id_info>
  <brief_title>ALaCART-B: Acute Leukemia and Chimeric Antigen Receptor-T Cell Therapy for B-lymphoblastic Leukemia.</brief_title>
  <acronym>ALaCART</acronym>
  <official_title>Chimeric-Antigen Receptor (CAR) T-Cell Therapy Using Multiple CARs and Cell Marker Profiling in High Risk and Relapsed/ Refractory B-Lineage Acute Lymphoblastic Leukaemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National University Hospital, Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National University Hospital, Singapore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the safety and efficacy of a immunophenotype-adapted&#xD;
      approach using CAR T-cells in patients with high-risk, refractory or relapsed B-lineage acute&#xD;
      lymphoblastic leukemia (B-ALL).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will receive CART-cells with one or more specificities according to the phenotypic&#xD;
      profile of the leukemic cells in each individual patient. This will allow targeting the&#xD;
      entire leukemia cell population to induce deeper and more durable remissions. Although it&#xD;
      would be possible to administer CART-cells targeting all possible antigens to all patients,&#xD;
      this indiscriminate approach would increase the CAR T-cell dose and hence, the risk of&#xD;
      toxicity in patients that could be effectively treated with a lower, less toxic, CAR T-cell&#xD;
      dose. Moreover, the cost of the procedure increases proportionally with the number of CAR&#xD;
      T-cells used, limiting our capacity to enrol other patients. Reducing the number of&#xD;
      CART-cells below the dose that we set, will inevitably increase the risk of treatment&#xD;
      failure, according to the literature and our own experience.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 28, 2021</start_date>
  <completion_date type="Anticipated">August 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2026</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participant who are flow cytometry minimal residual disease (MRD) negative at the end of 1 month after CAR T-cell infusion.</measure>
    <time_frame>30 days</time_frame>
    <description>MRD levels will be determined by flow cytometry, The target sensitivity of flow MRD is &lt;0.01% when available.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participant who are minimal residual disease (MRD) negative with molecular base assay at the end of 1 month after CAR T-cell infusion.</measure>
    <time_frame>30 days</time_frame>
    <description>MRD levels will be determined by molecular based MRD. PCR and oncogene fusion transcript (OFT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patient who shows CAR T-cell persistence and presence of B-cell aplasia by immunophenotyping using flow cytometry in bone marrow, peripheral blood and CSF samples at multiple study time points following CAR T cell infusion</measure>
    <time_frame>1 month to 5 years</time_frame>
    <description>Flow cytometry will be performed on bone marrow, peripheral blood and CSF samples at multiple study time points following CAR T cell infusion</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Lymphoblastic Leukemia, Acute, Childhood</condition>
  <condition>Lymphoblastic Leukemia</condition>
  <condition>Lymphoblastic Leukemia, Acute Adult</condition>
  <condition>Lymphoblastic Leukemia in Children</condition>
  <condition>CAR</condition>
  <condition>CAR T-Cell-Related Encephalopathy Syndrome</condition>
  <arm_group>
    <arm_group_label>Single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm Phase I Clinical Trial</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CAR T-cell therapy</intervention_name>
    <description>This is a single-centre, phase I study to determine the efficacy and safety of CAR T-cell therapy in patients with high-risk B-ALL, refractory or relapsed B-ALL.</description>
    <arm_group_label>Single arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Fulfil the Diagnosis/ Disease define as:&#xD;
&#xD;
               1. Relapsed B-cell acute lymphoblastic leukaemia/ lymphoma as defined by:&#xD;
&#xD;
                  Bone marrow disease = or &gt; 0.01% by MRD as determined by flow cytometry Or CNS&#xD;
                  disease as defined as &gt; 5 WBCs in CSF by morphology, or flow cytometric or&#xD;
                  molecular evidence of blasts or biopsy proven recurrence in the eye or brain.&#xD;
&#xD;
                  Or Extramedullary relapse as defined by morphological evidence of blasts in the&#xD;
                  testis or any other extramedullary sites&#xD;
&#xD;
               2. Induction failure as defined by Day 33/ End of induction:&#xD;
&#xD;
                  MRD ≥ 1% by flow cytometry on the Ma-Spore ALL 2020 protocol Or Failure to&#xD;
                  achieve morphological remission defined as &gt; 5% blasts after standard induction&#xD;
                  chemotherapy&#xD;
&#xD;
               3. Refractory disease as defined by:&#xD;
&#xD;
                  MRD ≥ 0.01% by flow cytometry or molecular methods during 2 or more timepoints&#xD;
                  after induction therapy&#xD;
&#xD;
               4. Any high risk features including :&#xD;
&#xD;
                  BCR-ABL1, BCR-ABL1-like, - ABL1-r, PDGFRB-r, TCF3-HLF, MLL-r, hypodiploid ALL (&lt;&#xD;
                  45 chromosomes), p53 pathogenic mutation as defined by RNA Seq or other molecular&#xD;
                  methods.&#xD;
&#xD;
               5. Patients who are unable to tolerate standard chemotherapy due to significant&#xD;
                  toxicity as well as other comorbidities&#xD;
&#xD;
          -  Minimum level of pulmonary reserve defined as grade ≤ 1 dyspnoea and oxygen saturation&#xD;
             of &gt; 95% on room air&#xD;
&#xD;
          -  Left ventricular systolic function ≥ 28% confirmed by echocardiogram, or left&#xD;
             ventricular ejection fraction ≥ 45% confirmed by echocardiogram within 3 months of&#xD;
             screening&#xD;
&#xD;
          -  Karnofsky (age ≥ 16 years) or Lansky (age &lt; 16 years) performance status ≥ 50 at&#xD;
             screening&#xD;
&#xD;
          -  Normal Age-adjusted eGFR Creatinine Clearance within 3 months of screening&#xD;
&#xD;
          -  Alanine aminotransferase ≤ 5 times the upper limit of normal for age&#xD;
&#xD;
          -  Patients with &gt; 99.9% of CD19 expression on blast cells will be eligible for anti-CD19&#xD;
             CAR T-cell infusion.&#xD;
&#xD;
          -  Patients with partial or absent CD19 expression (&lt; 99.9%) on blast cells will be&#xD;
             eligible to receive combinations of other CAR T-cells depending on the pattern of&#xD;
             antigen expression.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Failure to meet any of the inclusion criteria.&#xD;
&#xD;
          -  Patients who test positive on urine pregnancy testing and are pregnant or are&#xD;
             lactating&#xD;
&#xD;
          -  Concomitant genetic syndromes associated with BM failure states, such as Fanconi&#xD;
             anaemia, Kostmann syndrome, Schwachman syndrome, or any other BM failure syndrome with&#xD;
             the exception of Down syndrome&#xD;
&#xD;
          -  Prior malignancy, except carcinoma in situ of the skin or cervix treated with curative&#xD;
             intent and no evidence of active disease&#xD;
&#xD;
          -  Active or latent hepatitis B or active hepatitis C within 8 weeks of screening, or any&#xD;
             uncontrolled infection at screening&#xD;
&#xD;
          -  Positive HIV test within 8 weeks of screening&#xD;
&#xD;
          -  Grade 2 to 4 acute graft-vs-host disease (GVHD) or extensive chronic GVHD&#xD;
&#xD;
          -  Received an investigational medicinal product within 30 days of screening&#xD;
&#xD;
          -  Persistent disease or relapse after other forms of CAR-T cell therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Allen Yeoh, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>National University Hospital, Singapore</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dario Campana, M.D, PhD</last_name>
    <role>Study Director</role>
    <affiliation>National University, Singapore</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Allen Yeoh, M.D</last_name>
    <phone>+65 6772 2002</phone>
    <email>paeyej@nus.edu.sg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Allen Yeoh Eng Juh</name>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allen Yeoh, M.D</last_name>
      <phone>(+65) 6772 2002</phone>
      <email>paeyej@nus.edu.sg</email>
    </contact>
    <contact_backup>
      <last_name>Zhiwei Chen, BSc.</last_name>
      <phone>(+65) 6772 4406</phone>
      <email>chen.zhiwei@nus.edu.sg</email>
    </contact_backup>
    <investigator>
      <last_name>Bernice Oh, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Noriko Shimasaki, M.D, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michelle Poon, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Esther Chan, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elaine Coustan-Smith, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 26, 2021</study_first_submitted>
  <study_first_submitted_qc>September 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2021</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>B-ALL</keyword>
  <keyword>CAR-T cell therapy</keyword>
  <keyword>CAR T-cell therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

